¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"periventricular enhancement"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • periventricular nucleus
    ³ú½ÇÁÖÀ§ÇÙ
  • acoustic enhancement
    ¼Ò¸®Áõ°­, À½ÇâÁõ°­
  • contrast enhancement
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • edge enhancement
    °¡ÀåÀÚ¸®Áõ°­
  • enhancement
    1. ÃËÁø 2. Áõ°­ 3. °­È­
  • enhancement medium
    Áõ°­¹èÁö
  • oxygen enhancement ratio
    »ê¼ÒÈ¿°úÁõ°­·ü, »ê¼ÒÁõ°­ºñ
  • rim enhancement
    Å×Áõ°­
  • ring enhancement
    °í¸®Á¶¿µÁõ°­
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    Áõ°­, ÁõÁø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • periventricular enhancement
    ³ú½ÇÁÖÀ§Á¶¿µÁõ°­
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic enhancement
    ¼Ò¸®Áõ°­, À½ÇâÁõ°­
  • contrast enhancement
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • dense enhancement
    °­ÇÑÁ¶¿µÁõ°­
  • enhancement
    Áõ°­, ÁõÁø
  • edge enhancement
    °¡ÀåÀÚ¸®Áõ°­
  • enhancement medium
    Áõ°­¹èÁö
  • immunologic enhancement
    ¸é¿ª±âÇÇÀ¯µµ, ¸é¿ªÃËÁø
  • inflow enhancement
    À¯ÀÔÁõ°­
  • magnetic susceptibility proton relaxation enhancement
    ÀÚ±âÈ­À²¾ç¼ºÀÚÀÌ¿ÏÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • peripheral rim enhancement
    Å׵θ®Á¶¿µÁõ°­
  • rim enhancement
    Å×Áõ°­
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • OER [=oxygen enhancement ratio]
    »ê¼Ò°­È­À²
  • acoustic enhancement
    À½Çâ Áõ°­
  • immune enhancement
    ¸é¿ªÇÐÀûÃËÁø (Á¾¾çÁõ½ÄÀÇ)
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • immunological enhancement
    ¸é¿ªÁõ°­.
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­.
  • postanodal enhancement
    ¾ç±ØÈÄÁõ°­(åÕпý­ñòË­)
  • posterior echo enhancement
    ÈÄ¹æ ¿¡ÄÚ Áõ°­, ÈÄ¹æ ¸Þ¾Æ¸®Áõ°­
  • posterior echo enhancement
    ÈĹæ (ý­Û°) ¿¡ÄÚ Áõ°­ (ñòË­), ÈĹæ (ý­Û°) ¸Þ¾Æ¸® ?
  • rapid acquisition with relaxation enhancement (RARE)
    ±Þ¼Ó ȹµæ ÀÌ¿Ï Áõ°­
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • periventricular fibers
    ³ú½ÇÁÖÀ§¼¶À¯
  • periventricular glial limiting membrane
    ³ú½ÇÁÖÀ§¾Æ±³°æ°è¸·
  • periventricular system
    ³ú½ÇÁÖÀ§°è.
  • posterior periventricular nucleus
  • posterior periventricular nucleus
  • acoustic enhancement
    À½Çâ Áõ°­
  • contrast enhancement
    Á¶¿µ Áõ°­
  • contrast enhancement ratio
    Á¶¿µ Áõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­ ½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬ Áõ°­
  • enhancement
    Áõ°­
  • enhancement media
    Áõ°­¹èÁö
  • enhancement, immune
    ¸é¿ªÁõ°­Çö»ó
  • enhancement, immunological
    ¸é¿ªÁõ°­Çö»ó
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Periventricular fibers
    ³ú½ÇÁÖÀ§¼¶À¯
    [¿¾ ¿ë¾î] ½Ç¹æ¼¶À¯
  • Periventricular glial limiting membrane
    ³ú½ÇÁÖÀ§¾Æ±³°æ°è¸·
    [¿¾ ¿ë¾î] ³ú½ÇÁÖÀ§°æ°è¸·
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    Áõ°­(ñòË­)
  • enhancement effect
    Áõ°­ È¿°ú (ñòË­üùÍý)
  • fluorescence enhancement
    Çü±¤ Áõ°­(û«ÎÃñòË­)
  • immunological enhancement
    ¸é¿ª Áõ°­(Øóæ¹ñòË­)
  • migration enhancement factor
    À̵¿Ç×Áø ÀÎÀÚ(ì¹ÔÑùñòäì×í­)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acoustic enhancement
    À½ÇâÁõ°­
  • CE [=contrast enhancement]
    Á¶¿µÁõ°­
  • contrast enhancement [=CE]
    Á¶¿µÁõ°­
  • contrast enhancement ratio
    Á¶¿µÁõ°­ºñ
  • contrast enhancement scan
    Á¶¿µÁõ°­½ºÄµ
  • dense enhancement
    °­ÇÑ Á¶¿µÁõ°­
  • edge enhancement
    º¯¿¬Áõ°­
  • enhancement
    Áõ°­
  • flow related enhancement
    À¯µ¿°ü·ÃÁõ°­
  • gradient echo technique magnetic susceptibility proton relaxation enhancement
    °æ»ç¿¡ÄÚ¹ý±âÈ­À²¼ºÀÚÀÌ¿ÏÁõ°­
  • inflow enhancement
    À¯ÀÔÁõ°­
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÀÇÁ¶¿µÁõ°­
  • paradoxical enhancement
    ¿ª¼³ÀûÁ¶¿µÁõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º¾çÀÚÀÌ¿ÏÁõ°­
  • peripheral linear enhancement
    ¸»Ãʼ±ÇüÁ¶¿µÁõ°­
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
PIH periventricular-intraventricular hemorrhage; phenyl isopropylhydrazine; pregnancy-induced hypertensi...
PIVH peripheral intravenous hyperalimentation; periventricular-intraventricular hemorrhage
PVH periventricular hemorrhage; pulmonary venous hypertension
OER Oxygen Enhancement Ratio
ADE acute disseminated encephalitis; adverse drug event; antibody-dependent enhancement; apparent digest...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AVPV Anteroventral periventricular nucleus
PVH Periventricular haemorrhage
PVL Periventricular leucomalacia
PeN Periventricular nucleus
PIVH Periventricular-intraventricular hemorrhage
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • periventricular
    ½Ç ÁÖÀ§ÀÇ
  • periventricular glial limiting membrane
    ³ú½Ç ÁÖÀ§ ¾Æ±³ °æ°è¸·
  • periventricular hypothalamus
    ³ú½Ç ÁÖÀ§ ½Ã»ó ÇϺÎ
  • acoustic enhancement
    À½Çâ Áõ°­
  • contrast enhancement
    Á¶¿µ Áõ°­
  • contrast enhancement scan
    Á¶¿µ Áõ°­ ½ºÄµ
  • edge enhancement
    °è¸é Áõ°­
  • immunological enhancement
    ¸é¿ª Áõ°­ Çö»ó, ¸é¿ª Áõ°­
    ¸é¿ª ¹ÝÀÀÀÇ ¼öÁØÀ» Áõ´ë½ÃŰ´Â ¿©·¯ °¡Áö ƯÀÌÀû ¶Ç´Â ºñƯÀÌÀû »óȲ.
  • minimal enhancement
    ¹Ì¹ÌÇÑ Á¶¿µ Áõ°­, °æµµÀÇ Á¶¿µ Áõ°­
  • paradoxical enhancement
    ¿ª¼³Àû Á¶¿µ Áõ°­
  • paramagnetic proton relaxation enhancement
    »óÀÚ¼º ¾çÀÚ ÀÌ¿Ï Áõ°­
  • peripheral linear enhancement
    ¸»ÃÊ ¼±Çü Á¶¿µ Áõ°­
  • peripheral rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • rim enhancement
    Å׵θ® Á¶¿µ Áõ°­
  • ring enhancement
    ȯ»ó Á¶¿µ Áõ°­
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 1
periventricular fibres A heterogeneous system of thin nerve fibres in the periventricular gray matter of the hypothalamus; the dorsal longitudinal fasciculus is a caudal continuation of the system.
Synonym: fibrae periventriculares.
(05 Mar 2000)
posterior periventricular nucleus A nucleus located in the middle hypothalamus in the most ventral part of the third ventricle near the entrance of the infundibular recess. Its small cells are in close contact with the ependyma.
(12 Dec 1998)
leukomalacia, periventricular A disease of premature or newborn infants hypoxic and ischemic in nature and leading to infarction of brain white matter and cerebral ventricle enlargement.
(12 Dec 1998)
acoustic enhancement A manifestation of increased acoustic signal amplitude returning from regions beyond an object which causes little or no attenuation of the sound beam.
Compare: acoustic shadow.
(05 Mar 2000)
antibody-dependent enhancement Enhancement of viral infectivity caused by non-neutralizing antibodies. There are at least two mechanisms known to account for this: mediation by fc receptors (receptors, fc) or by complement receptors (receptors, complement). Either the virus is complexed with antiviral IgG and binds to fc receptors, or virus is coated with antiviral IgM and binds to complement receptors.
(12 Dec 1998)
radiographic image enhancement Improvement in the quality of an X-ray image by use of an intensifying screen, tube, or filter and by optimum exposure techniques. Digital processing methods are often employed.
(12 Dec 1998)
graft enhancement, immunologic The induction of prolonged survival and growth of allografts of either tumours or normal tissues which would ordinarily be rejected. It may be induced passively by introducing graft-specific antibodies from previously immunised donors, which bind to the graft's surface antigens, masking them from recognition by T-cells; or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity.
(12 Dec 1998)
ring enhancement In computed tomography, when a bright circle appears on an image made after injection of contrast medium, characteristic of localization of the contrast in the wall of an abscess.
(05 Mar 2000)
contrast enhancement The intravenous administration of water-soluble iodinated contrast material, which increases the CT number of the vascular pool, as well as some lesions (particularly in the brain), due to abnormal leakage into the interstitium; the property of showing increased radiopacity from concentration of contrast medium.
(05 Mar 2000)
image enhancement Improvement of the quality of a picture by various techniques, including computer processing, digital filtering, echocardiographic techniques, light and ultrastructural microscopy, fluorescence spectrometry and microscopy, scintigraphy, and in vitro image processing at the molecular level.
(12 Dec 1998)
immunological enhancement In immunology, the potentiating effect of specific antibody in establishing and in delaying rejection of a tumour allograft; aside from antibody, non-specific substances may also act to enhance immune response.
Synonym: immunological enhancement.
(05 Mar 2000)
edge enhancement Using analogue or digital image processing to increase the contrast of each interface; equivalent to using a high-pass filter.
(05 Mar 2000)
enhancement Altering an object, substance or site for the improvement of a specific value.
(09 Oct 1997)
enhancement effect Property of higher plant photosynthesis, discovered by Robert Emerson. The quantum yield of red light (less than 680nm) and far red light (700nm), when shone simultaneously on a plant, is greater than the sum of the yields of the light of the two wavelengths separately. This effect provides evidence for the cooperative interaction of two photosystems in photosynthesis.
(18 Nov 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • enhancement
    (°¡°Ý,¸Å·Â,°¡Ä¡ µîÀÇ)»ó½Â;µî±Í;Çâ»ó;Áõ´ë
  • revenue enhancement
    ¼¼ÀÔ Áõ°¡(Áõ¼¼¶ó´Â ¸» ´ë½Å ¾²´Â Ç¥Çö)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á